Celso L Diaz1, Pelin Cinar2, Jimmy Hwang3, Andrew H Ko2, Margaret A Tempero2. 1. School of Medicine, University of California. 2. Department of Medicine, Division of Hematology/Oncology, University of California. 3. UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.
Abstract
OBJECTIVE: The objective of this study was to determine the features of carbohydrate antigen (CA) 19-9 decline that correlates best with survival benefit in patients with metastatic pancreatic cancer. METHODS: This is a retrospective study of 225 patients with metastatic pancreatic cancer receiving first-line therapy. Analysis was performed by the Kaplan-Meier method and Cox-proportional hazards ratios. CA 19-9 decline was grouped into quartiles within different CA 19-9 baseline groups. Time to nadir and CA 19-9 decline at month-2 (M2) of therapy were evaluated for patients with a baseline level ≥1000 U/mL. RESULTS: No significant trend in survival was observed across baseline CA 19-9 levels. The greatest survival benefit was seen with a ≥75% decline to nadir. Among those with a ≥75% decline and baseline ≥1000 U/mL, 43 of 57 patients had a >50% decline at M2 of therapy and additional survival benefit was observed with a slower decline to nadir. Small sample sizes limited analysis of other baseline groups. CA 19-9 decline at M2 was not predictive. CONCLUSIONS: In patients with a CA 19-9 ≥1000 U/mL, serial CA 19-9 levels may be considered as a surrogate for serial imaging to evaluate treatment response, with a ≥75% decline indicating the greatest survival benefit. Survival was improved further in the setting of a slower decline to nadir with the highest benefit seen in patients with a nadir occurring at 4 months or longer.
OBJECTIVE: The objective of this study was to determine the features of carbohydrate antigen (CA) 19-9 decline that correlates best with survival benefit in patients with metastatic pancreatic cancer. METHODS: This is a retrospective study of 225 patients with metastatic pancreatic cancer receiving first-line therapy. Analysis was performed by the Kaplan-Meier method and Cox-proportional hazards ratios. CA 19-9 decline was grouped into quartiles within different CA 19-9 baseline groups. Time to nadir and CA 19-9 decline at month-2 (M2) of therapy were evaluated for patients with a baseline level ≥1000 U/mL. RESULTS: No significant trend in survival was observed across baseline CA 19-9 levels. The greatest survival benefit was seen with a ≥75% decline to nadir. Among those with a ≥75% decline and baseline ≥1000 U/mL, 43 of 57 patients had a >50% decline at M2 of therapy and additional survival benefit was observed with a slower decline to nadir. Small sample sizes limited analysis of other baseline groups. CA 19-9 decline at M2 was not predictive. CONCLUSIONS: In patients with a CA 19-9 ≥1000 U/mL, serial CA 19-9 levels may be considered as a surrogate for serial imaging to evaluate treatment response, with a ≥75% decline indicating the greatest survival benefit. Survival was improved further in the setting of a slower decline to nadir with the highest benefit seen in patients with a nadir occurring at 4 months or longer.
Authors: Ipek Alpertunga; Rabail Sadiq; Deep Pandya; Tammy Lo; Maxim Dulgher; Sarah Evans; Bridget Bennett; Nancy Rennert; Richard C Frank Journal: Front Oncol Date: 2021-02-25 Impact factor: 6.244
Authors: Sidsel C Lindgaard; Emil Maag; Zsófia Sztupinszki; Inna M Chen; Astrid Z Johansen; Benny V Jensen; Stig E Bojesen; Dorte L Nielsen; Zoltan Szallasi; Julia S Johansen Journal: Cancers (Basel) Date: 2022-07-01 Impact factor: 6.575
Authors: Patrick Kirchweger; Alexander Kupferthaler; Jonathan Burghofer; Gerald Webersinke; Emina Jukic; Simon Schwendinger; Helwig Wundsam; Matthias Biebl; Andreas Petzer; Holger Rumpold Journal: Front Oncol Date: 2022-08-30 Impact factor: 5.738